Floatz logo

IMMUNOGLOBULIN G4, ANTI-(HUMAN ANTIGEN RECEPTOR KIR (KILLER CELL IMMUNOGLOBULIN-LIKE)) (HUMAN MONOCLONAL ANTI-KIR(1-7F9) HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL ANTI-KIR(1-7F9) LIGHT CHAIN, DIMER

Acute Myeloid Leukemia

Innate Pharmamonoclonal_antibodyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
59/ 100

Competitive context

685 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

IMMUNOGLOBULIN G4, ANTI-(HUMAN ANTIGEN RECEPTOR KIR (KILLER CELL IMMUNOGLOBULIN-LIKE)) (HUMAN MONOCLONAL ANTI-KIR(1-7F9) HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL ANTI-KIR(1-7F9) LIGHT CHAIN, DIMER is also rated in:

smoldering plasma cell myelomaDormant
B
Indicative ·
57 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
53 / 100
View asset →
First or Second RelapseDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →